The KCNK9 antibody targets the protein product of the KCNK9 gene, which encodes the TASK3 potassium channel, a member of the two-pore domain (K2P) potassium channel family. TASK3 channels play a critical role in maintaining resting membrane potential and regulating cellular excitability, particularly in neurons and endocrine cells. Dysregulation of KCNK9 expression has been linked to several pathologies, including cancer and neurodevelopmental disorders. Overexpression of KCNK9 is observed in multiple cancers, such as breast, lung, and neuroblastoma, where it promotes cell proliferation and survival, suggesting its potential as a therapeutic target. Conversely, loss-of-function mutations or imprinting defects in KCNK9 are associated with Birk-Barel syndrome, a rare genetic disorder characterized by intellectual disability, hypotonia, and distinct facial features. Antibodies against KCNK9 are widely used in research to study TASK3 expression patterns, subcellular localization, and functional interactions in both normal and diseased tissues. They enable techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding in the validation of KCNK9 as a biomarker or drug target. Recent studies also explore therapeutic applications, such as blocking KCNK9 activity in cancer using monoclonal antibodies or small-molecule inhibitors. Despite progress, challenges remain in understanding tissue-specific roles and designing selective modulators to minimize off-target effects.